VICTORIA / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) has announced the purchase of its second state-of-the-art Intellicyt® iQue Screener PLUS for high-throughput cell-based screening.

The demand for accelerated development of next-generation antibodies that recognize evermore challenging targets and have improved activities has prompted IPA to purchase further instrumentation to evaluate more antibody characteristics in a multiplexed, high-throughput way. Traditional antibody screening tools report on binding one target at a time, which makes the discovery process time consuming and can require large amounts of target protein. The Intellicyt iQue allows IPA scientists to significantly reduce lead discovery time while conserving valuable samples and reducing reagent cost.

“The decision to acquire a second Intellicyt iQue [now for North America] will further support IPA’s strategic vision of continued growth and expansion in providing end-to-end therapeutic antibody discovery services to a rapidly expanding list of pharma and biotech clients.” said Jennifer Bath, CEO and President of ImmunoPrecise Antibodies.
The iQue Screener PLUS can analyze antibodies developed from all of IPA’s antibody discovery platforms, hybridoma, B cell select, and phage display, on cells or beads in suspension. The early stage screening of antibodies on cell surface targets provides more predictable data and enables the selection of lead candidate drugs earlier and faster. In addition, the iQue provides early data on the activities of lead drugs to improve the probability for downstream successes.

About ImmunoPrecise Antibodies Ltd.

ImmunoPrecise is a full-service, therapeutic and diagnostic antibody discovery company focused on the next generation of antibody discovery, to deliver the most relevant antibodies, in a shorter period of time, with the highest probability of succeeding through clinical validation.
ImmunoPrecise Antibodies Ltd operates from three state-of-the-art laboratory facilities. ImmunoPrecise Antibodies (Canada) is located in Victoria, British Columbia, while U-Protein Express B.V., and ModiQuest Research B.V. are located in Utrecht and Oss, Netherlands, respectively. The Company operates globally to offer antibody services from target analysis to pre-clinical studies.

The services offered to clients include antibody discovery for a broad spectrum of antigens, including challenging targets. Among these services, the Company offers antibody development directly from B-cells (B-Cell Select), through phage display, and by hybridoma production. The Company also provides a broad range of supporting services including immunologically-based assays, recombinant protein manufacturing, humanization, optimization, stable cell line development, and advanced solutions to challenges faced by clients in antibody-related research and development. The antibodies produced by ImmunoPrecise target a wide variety of therapeutic, diagnostic and research applications.